Kalaris Therapeutics Inc
KLRS
查看详细走势图
10.060USD
+0.930+10.19%
收盘 12/22, 16:00（美东）报价延迟15分钟
188.15M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+10.19%
5天
+13.42%
1月
+43.51%
6月
+319.17%
今年开始到现在
+4.14%
1年
+8.27%
查看详细走势图
TradingKey Kalaris Therapeutics Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Kalaris Therapeutics Inc当前公司基本面数据相对非常健康，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名133/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价17.00。中期看，股价处于上升通道。近一个月，市场表现很强，技术面评分较高，但很强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Kalaris Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
5
位分析师
买入
评级
17.000
目标均价
+175.97%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Kalaris Therapeutics Inc亮点
亮点风险
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Kalaris Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Kalaris Therapeutics Inc简介
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
公司代码KLRS
公司Kalaris Therapeutics Inc
CEOOxtoby (Andrew)
网址https://kalaristx.com/
常见问题
Kalaris Therapeutics Inc(KLRS)的当前股价是多少？
Kalaris Therapeutics Inc(KLRS)的当前股价是 10.060。
Kalaris Therapeutics Inc的股票代码是什么？
Kalaris Therapeutics Inc的股票代码是KLRS。
Kalaris Therapeutics Inc股票的52周最高点是多少？
Kalaris Therapeutics Inc股票的52周最高点是12.900。
Kalaris Therapeutics Inc股票的52周最低点是多少？
Kalaris Therapeutics Inc股票的52周最低点是2.140。
Kalaris Therapeutics Inc的市值是多少？
Kalaris Therapeutics Inc的市值是188.15M。
Kalaris Therapeutics Inc的净利润是多少？
Kalaris Therapeutics Inc的净利润为-58.77M。
现在Kalaris Therapeutics Inc(KLRS)的股票是买入、持有还是卖出？
根据分析师评级，Kalaris Therapeutics Inc(KLRS)的总体评级为买入，目标价格为17.000。
Kalaris Therapeutics Inc(KLRS)股票的每股收益（EPS TTM）是多少
Kalaris Therapeutics Inc(KLRS)股票的每股收益（EPS TTM）是-236.854。
相关品种
